2025-524439-38-00招募中2 期
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 16
- 主要终点
- Disease-free survival (DFS) is defined as time from surgery to local or distal recurrence, death due to lung cancer or censoring.
研究概览
简要总结
To compare the disease-free survival (DFS) for patients with RVT 1-60% in the two treatment arms evaluated 36 months after last patient included (LPI).
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Participant must be 18 years of age or older, at the time of signing the informed consent.
- •Body weight >30kg.
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Patients with stage II-III NSCLC evaluated at an MDT as having high risk of relapse.
- •Resectability: It should be deemed possible to obtain free margins after resection (R0) evaluated by the MDT-meeting.
- •ECOG performance status 0-
- •Known negative status of ALK and EGFR by approved assays (this includes a positive KRAS mutation status which is considered a surrogate marker for negative EGFR/ALK).
- •Operability: The patients should be deemed operable by an MDT according to national guidelines.
- •Women of childbearing potential (WOCBP) should use a highly effective method during the treatment period and for at least 5 months after the last dose of immunotherapy to avoid pregnancy. Methods considered as highly effective birth control methods include combined (oestrogen and progestogen containing) or progestogen-only hormonal contraception associated with inhibition of ovulation (oral, intravaginal, injectable, implantable or transdermal), intrauterine device (including hormone-releasing), bilateral tubal occlusion, vasectomised partner or sexual abstinence
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (eg, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •Participants should have adequate organ and bone marrow function defined as in protocol.
排除标准
- •Patients that are medically inoperable.
- •Treatment with any investigational medicinal product (IMP) that may interfere with the study treatment, within 1 month or 5 half-lives prior to first study drug administration (whichever is longer) prior to first administration of study drug.
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
- •History of another primary malignancy except for: a)Malignancy treated with curative intent and with no known active disease ≥3 years before the first dose of IP and of low potential risk for recurrence b)Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease c)Adequately treated carcinoma in situ without evidence of disease d)Low-grade prostate cancer defined as observed with watchful waiting or treated with curative intent and Gleason ≤
- •Patients with known targetable mutations in EGFR or ALK.
- •Participant has received a live vaccine within 30 days of planned start of study therapy. COVID-19 vaccines that do not contain live viruses are allowed. Note: mRNA and adenoviral-based COVID-19 vaccines are considered non-live.
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: a)Patients with vitiligo or alopecia b)Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement c)Any chronic skin condition that does not require systemic therapy d)Patients without active disease in the last 2 years may be included but only after consultation with the study physician e)Patients with celiac disease controlled by diet alone f)A rheumatologist is consulted and immunotherapy is not deemed a risk for the disease.
- •Uncontrolled intercurrent illness that would prevent the use of chemotherapy and/or immunotherapy, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- •History of active primary immunodeficiency.
- •Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Adjust wording as necessary and consider evaluating at screening for studies with known hepatotoxicity or other relevant requirements.
- •Participants co-infected with HBV and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and/or anti HBcAb with detectable HBV DNA); AND a)HCV positive (presence of anti-HCV antibodies); OR b)HDV positive (presence of anti-HDV antibodies)..
- •Pregnancy or lactation.
- •Subjects with HBV infection, characterised by positive HBsAg and/or anti-HBcAb with detectable HBV DNA (≥ 10 IU/ml or above the limit of detection per local laboratory standard), must be treated with antiviral therapy, per institutional practice. Following antiviral therapy initiation, subjects must show adequate viral suppression (ie, HBV DNA ≤ 2000 IU/mL) as prior to randomisation. Participants will remain on antiviral therapy for the study duration and for 6 months after the last dose of IP.
- •Subjects with HBV infection, characterised by positive HBsAg and/or anti-HBcAb with undetectable HBV DNA (< 10 IU/ml or under the limit of detection per local lab standard) do not require antiviral therapy prior to randomisation. These subjects will be tested at every cycle to monitor HBV DNA levels; if HBV DNA is detected (≥ 10 IU/ml or above the limit of detection per local lab standard), antiviral therapy must be initiated, continued for the study duration and for 6 months after the last dose of IP.
- •Known HIV infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load (below 50 or the limit of detection for 12 weeks, CD4+ count of ≥350 cells/mm3, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. For biologics or other long-acting immunosuppressive agents a washout period of at least 28 days or 5 half-lives (whichever is longer) should be all allowed.The following are exceptions to this criterion: a)Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articularection) b)Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent c)Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- •Hypersensitivity to durvalumab or any of its excipients.
- •Any reason why, in the opinion of the investigator, the patient should not participate.
- •Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. a)Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. b)Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician.
- •Participant has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal/gastric varices, or persistent jaundice. Note: Stable non-cirrhotic chronic liver disease (including Gilbert’s syndrome or asymptomatic gallstones) is acceptable if participant otherwise meets entry criteria.
- •Participant has experienced any of the following with prior immunotherapy: any immune related AE (irAE) of Grade 3 or higher, immune-related severe neurologic events of any grade (e.g., myasthenic syndrome/myasthenia gravis, encephalitis, Guillain Barré syndrome, or transverse myelitis), exfoliative dermatitis of any grade (SJS, TEN, or DRESS syndrome), or myocarditis of any grade. Non–clinically significant laboratory abnormalities are not exclusionary.
- •Immunocompromised patients are not allowed.
- •Clinically significant cardiovascular disease within 6 months of enrolment.
- •Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
研究组 & 干预措施
IMFINZI 50 mg/mL concentrate for solution for infusion
Test
干预措施: IMFINZI 50 mg/mL concentrate for solution for infusion (Drug)
结局指标
主要结局
Disease-free survival (DFS) is defined as time from surgery to local or distal recurrence, death due to lung cancer or censoring.
Disease-free survival (DFS) is defined as time from surgery to local or distal recurrence, death due to lung cancer or censoring.
次要结局
- Disease-free survival (DFS) is defined as time from surgery to local or distal recurrence, death due to lung cancer or censoring.
- Overall survival (OS) is defined as time from surgery to death due to lung cancer or censoring.
- Proportion of patients with detection of ctDNA post-surgery and 12 months after surgery.
- Proportion of patients with maintained or improved level of health-related quality of life at 12 months after surgery.
- Proportion of patients with maintained or improved level of dyspnoea at 12 months after surgery.
- The primary outcome is the incremental cost-effectiveness ratio (ICER), defined as the incremental cost per quality-adjusted life year (QALY) gained in each treatment arm over a lifetime horizon from a Norwegian healthcare perspective. Secondary outcomes include overall QALYs gained and total costs - stratified by treatment arm.
- Adverse events grade 3-5.
研究者
Vilde Haakensen
Scientific
Oslo Universitetssykehus HF
研究点 (16)
Loading locations...
相似试验
招募中
4 期
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.schizophrenia, schizoaffective disorder, schizophrenifom disorder2023-506602-39-00Universitair Medisch Centrum Utrecht310
尚未招募
2 期
A Comparative Non Randomized clinical trial on Akkini Chooranam and Narambu Pidikku Ottradam and Varmam Adangal alone in the management of Korai Vatham (Lumbar Spondylosis) for the patients reporting at Government Siddha Medical college and Hospital PalayamkottaiOther spondylosis,CTRI/2026/04/107449Government Siddha Medical College and Hospital Palayamkottai40
招募中
3 期
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants with Solid and Hematologic CancersCancer Associated Thrombosis2024-519299-16-00Regeneron Pharmaceuticals Inc.164
尚未招募
3 期
Study the wound healing effect of ayurvedic medicine on wound of opening of uterusInflammatory disease of cervix uteri. Ayurveda Condition: VRANAH,CTRI/2024/04/065462Dr Archana Subhash Jadhav156
进行中（未招募）
不适用
A study comparing two ayurvedic procedures using masha saindhava taila in the management of knee joint painCTRI/2026/07/113453Dr Pooja Patil50